Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND & AIMS: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects intestinal cells, and might affect the intestinal microbiota. We investigated changes in the fecal fungal microbiomes (mycobiome) of patients with SARS-CoV-2 infection during hospitalization and on recovery.
METHODS: We performed deep shotgun metagenomic sequencing analysis of fecal samples from 30 patients with coronavirus disease 2019 (COVID-19) in Hong Kong, from February 5 through May 12, 2020. Fecal samples were collected 2 to 3 times per week from time of hospitalization until discharge. We compared fecal mycobiome compositions of patients with COVID-19 with those from 9 subjects with community-acquired pneumonia and 30 healthy individuals (controls). We assessed fecal mycobiome profiles throughout time of hospitalization until clearance of SARS-CoV-2 from nasopharyngeal samples.
RESULTS: Patients with COVID-19 had significant alterations in their fecal mycobiomes compared with controls, characterized by enrichment of Candia albicans and a highly heterogeneous mycobiome configuration, at time of hospitalization. Although fecal mycobiomes of 22 patients with COVID-19 did not differ significantly from those of controls during times of hospitalization, 8 of 30 patients with COVID-19 had continued significant differences in fecal mycobiome composition, through the last sample collected. The diversity of the fecal mycobiome of the last sample collected from patients with COVID-19 was 2.5-fold higher than that of controls (P < .05). Samples collected at all timepoints from patients with COVID-19 had increased proportions of opportunistic fungal pathogens, Candida albicans, Candida auris, and Aspergillus flavus compared with controls. Two respiratory-associated fungal pathogens, A. flavus and Aspergillus niger, were detected in fecal samples from a subset of patients with COVID-19, even after clearance of SARS-CoV-2 from nasopharyngeal samples and resolution of respiratory symptoms.
CONCLUSIONS: In a pilot study, we found heterogeneous configurations of the fecal mycobiome, with enrichment of fungal pathogens from the genera Candida and Aspergillus, during hospitalization of 30 patients with COVID-19 compared with controls. Unstable gut mycobiomes and prolonged dysbiosis persisted in a subset of patients with COVID-19 up to 12 days after nasopharyngeal clearance of SARS-CoV-2. Studies are needed to determine whether alterations in intestinal fungi contribute to or result from SARS-CoV-2 infection, and the effects of these changes in disease progression.
| Errataetall: |
CommentIn: Gastroenterology. 2021 May;160(6):2195. - PMID 33387514 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:159 |
|---|---|
| Enthalten in: |
Gastroenterology - 159(2020), 4 vom: 20. Okt., Seite 1302-1310.e5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zuo, Tao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.11.2020 Date Revised 01.04.2024 published: Print-Electronic CommentIn: Gastroenterology. 2021 May;160(6):2195. - PMID 33387514 Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.gastro.2020.06.048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311769659 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311769659 | ||
| 003 | DE-627 | ||
| 005 | 20240401231853.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.gastro.2020.06.048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM311769659 | ||
| 035 | |a (NLM)32598884 | ||
| 035 | |a (PII)S0016-5085(20)34852-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zuo, Tao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2020 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Gastroenterology. 2021 May;160(6):2195. - PMID 33387514 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects intestinal cells, and might affect the intestinal microbiota. We investigated changes in the fecal fungal microbiomes (mycobiome) of patients with SARS-CoV-2 infection during hospitalization and on recovery | ||
| 520 | |a METHODS: We performed deep shotgun metagenomic sequencing analysis of fecal samples from 30 patients with coronavirus disease 2019 (COVID-19) in Hong Kong, from February 5 through May 12, 2020. Fecal samples were collected 2 to 3 times per week from time of hospitalization until discharge. We compared fecal mycobiome compositions of patients with COVID-19 with those from 9 subjects with community-acquired pneumonia and 30 healthy individuals (controls). We assessed fecal mycobiome profiles throughout time of hospitalization until clearance of SARS-CoV-2 from nasopharyngeal samples | ||
| 520 | |a RESULTS: Patients with COVID-19 had significant alterations in their fecal mycobiomes compared with controls, characterized by enrichment of Candia albicans and a highly heterogeneous mycobiome configuration, at time of hospitalization. Although fecal mycobiomes of 22 patients with COVID-19 did not differ significantly from those of controls during times of hospitalization, 8 of 30 patients with COVID-19 had continued significant differences in fecal mycobiome composition, through the last sample collected. The diversity of the fecal mycobiome of the last sample collected from patients with COVID-19 was 2.5-fold higher than that of controls (P < .05). Samples collected at all timepoints from patients with COVID-19 had increased proportions of opportunistic fungal pathogens, Candida albicans, Candida auris, and Aspergillus flavus compared with controls. Two respiratory-associated fungal pathogens, A. flavus and Aspergillus niger, were detected in fecal samples from a subset of patients with COVID-19, even after clearance of SARS-CoV-2 from nasopharyngeal samples and resolution of respiratory symptoms | ||
| 520 | |a CONCLUSIONS: In a pilot study, we found heterogeneous configurations of the fecal mycobiome, with enrichment of fungal pathogens from the genera Candida and Aspergillus, during hospitalization of 30 patients with COVID-19 compared with controls. Unstable gut mycobiomes and prolonged dysbiosis persisted in a subset of patients with COVID-19 up to 12 days after nasopharyngeal clearance of SARS-CoV-2. Studies are needed to determine whether alterations in intestinal fungi contribute to or result from SARS-CoV-2 infection, and the effects of these changes in disease progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coronovirus | |
| 650 | 4 | |a Intestine | |
| 650 | 4 | |a Microbe | |
| 650 | 4 | |a Yeast | |
| 650 | 7 | |a DNA, Fungal |2 NLM | |
| 700 | 1 | |a Zhan, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Tso, Eugene Y K |e verfasserin |4 aut | |
| 700 | 1 | |a Lui, Grace C Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Wenqi |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Francis K L |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Paul K S |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Siew C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterology |d 1945 |g 159(2020), 4 vom: 20. Okt., Seite 1302-1310.e5 |w (DE-627)NLM00001706X |x 1528-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:159 |g year:2020 |g number:4 |g day:20 |g month:10 |g pages:1302-1310.e5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.gastro.2020.06.048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 159 |j 2020 |e 4 |b 20 |c 10 |h 1302-1310.e5 | ||